Dyskinesia - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 170
Inquire Before Buying

Global Markets Direct's, ‘Dyskinesia - Pipeline Review, H2 2016', provides an overview of the Dyskinesia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dyskinesia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dyskinesia

  • The report reviews pipeline therapeutics for Dyskinesia by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Dyskinesia therapeutics and enlists all their major and minor projects

  • The report assesses Dyskinesia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Dyskinesia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Dyskinesia

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Dyskinesia pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Dyskinesia - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Dyskinesia Overview 8
Therapeutics Development 9
Pipeline Products for Dyskinesia - Overview 9
Pipeline Products for Dyskinesia - Comparative Analysis 10
Dyskinesia - Therapeutics under Development by Companies 11
Dyskinesia - Therapeutics under Investigation by Universities/Institutes 14
Dyskinesia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Dyskinesia - Products under Development by Companies 18
Dyskinesia - Products under Investigation by Universities/Institutes 21
Dyskinesia - Companies Involved in Therapeutics Development 22
Adamas Pharmaceuticals, Inc. 22
Addex Therapeutics Ltd 23
Advicenne 24
Astraea Therapeutics, LLC 25
Bionomics Limited 26
Catalyst Biosciences, Inc. 27
Catalyst Pharmaceuticals, Inc. 28
Clevexel Pharma SAS 29
Contera Pharma ApS 30
EpiVax, Inc. 31
Heptares Therapeutics Limited 32
Hua Medicine (Shanghai) Ltd. 33
Integrative Research Laboratories Sweden AB 34
Ipsen S.A. 35
Merz Pharma GmbH & Co. KgaA 36
MitoDys Therapeutics Limited 37
Neurim Pharmaceuticals Ltd 38
Neurocrine Biosciences, Inc. 39
Neurolixis Inc. 40
Osmotica Pharmaceutical Corp. 41
Otsuka Holdings Co., Ltd. 42
Phenomenome Discoveries, Inc. 43
Revance Therapeutics, Inc. 44
Sage Therapeutics, Inc. 45
SciFluor Life Sciences, LLC 46
SOM Innovation Biotech SL 47
Synchroneuron Inc. 48
Teva Pharmaceutical Industries Ltd. 49
Dyskinesia - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
(dextromethorphan + quinidine sulfate) - Drug Profile 62
A2M-13677 - Drug Profile 67
abobotulinumtoxin A - Drug Profile 68
acamprosate calcium SR - Drug Profile 72
amantadine hydrochloride ER - Drug Profile 74
amantadine hydrochloride ER - Drug Profile 80
AT-127 - Drug Profile 81
AT-326 - Drug Profile 82
AT-403 - Drug Profile 83
befiradol - Drug Profile 84
CPP-115 - Drug Profile 86
CVXL-0107 - Drug Profile 90
deutetrabenazine ER - Drug Profile 91
dipraglurant ER - Drug Profile 95
dipraglurant IR - Drug Profile 96
Drug for Dyskinesia - Drug Profile 100
HTL-14242 - Drug Profile 101
incobotulinumtoxin A - Drug Profile 102
IRL-790 - Drug Profile 105
JM-010 - Drug Profile 106
MLR-1019 - Drug Profile 108
NBI-640756 - Drug Profile 109
Neu-120 - Drug Profile 110
Neu-240 - Drug Profile 111
onabotulinumtoxinA - Drug Profile 112
PEUN-3 - Drug Profile 113
PPI-1011 - Drug Profile 114
remeglurant - Drug Profile 115
RT-002 - Drug Profile 116
SAGE-217 - Drug Profile 118
sepranolone - Drug Profile 120
SK-609 - Drug Profile 127
Small Molecule for Dyskinesia - Drug Profile 128
Small Molecule for Dyskinesia and Hyperkinesia - Drug Profile 129
Small Molecules for Neurodegenerative Disease - Drug Profile 130
Small Molecules for Tardive Dyskinesia - Drug Profile 131
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 132
Small Molecules to Antagonize M1 Muscarinic Acetylcholine Receptor for Dystonia - Drug Profile 133
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 134
Small Molecules to Antagonize mGluR5 for Dyskinesia - Drug Profile 135
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 136
SOM-3355 - Drug Profile 137
TC-8831 - Drug Profile 138
tetrabenazine - Drug Profile 139
valbenazine tosylate - Drug Profile 140
Dyskinesia - Dormant Projects 146
Dyskinesia - Discontinued Products 149
Dyskinesia - Product Development Milestones 150
Featured News & Press Releases 150
Appendix 165
Methodology 165
Coverage 165
Secondary Research 165
Primary Research 165
Expert Panel Validation 165
Contact Us 165
Disclaimer 166

List of Tables

Number of Products under Development for Dyskinesia, H2 2016 13
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 16
Number of Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Development, H2 2016 21
Products under Development by Companies, H2 2016 22
Products under Development by Companies, H2 2016 (Contd..1) 23
Products under Development by Companies, H2 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H2 2016 25
Dyskinesia - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 26
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2016 27
Dyskinesia - Pipeline by Advicenne, H2 2016 28
Dyskinesia - Pipeline by Astraea Therapeutics, LLC, H2 2016 29
Dyskinesia - Pipeline by Bionomics Limited, H2 2016 30
Dyskinesia - Pipeline by Catalyst Biosciences, Inc., H2 2016 31
Dyskinesia - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 32
Dyskinesia - Pipeline by Clevexel Pharma SAS, H2 2016 33
Dyskinesia - Pipeline by Contera Pharma ApS, H2 2016 34
Dyskinesia - Pipeline by EpiVax, Inc., H2 2016 35
Dyskinesia - Pipeline by Heptares Therapeutics Limited, H2 2016 36
Dyskinesia - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 37
Dyskinesia - Pipeline by Integrative Research Laboratories Sweden AB, H2 2016 38
Dyskinesia - Pipeline by Ipsen S.A., H2 2016 39
Dyskinesia - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 40
Dyskinesia - Pipeline by MitoDys Therapeutics Limited, H2 2016 41
Dyskinesia - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016 42
Dyskinesia - Pipeline by Neurocrine Biosciences, Inc., H2 2016 43
Dyskinesia - Pipeline by Neurolixis Inc., H2 2016 44
Dyskinesia - Pipeline by Osmotica Pharmaceutical Corp., H2 2016 45
Dyskinesia - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 46
Dyskinesia - Pipeline by Phenomenome Discoveries, Inc., H2 2016 47
Dyskinesia - Pipeline by Revance Therapeutics, Inc., H2 2016 48
Dyskinesia - Pipeline by Sage Therapeutics, Inc., H2 2016 49
Dyskinesia - Pipeline by SciFluor Life Sciences, LLC, H2 2016 50
Dyskinesia - Pipeline by SOM Innovation Biotech SL, H2 2016 51
Dyskinesia - Pipeline by Synchroneuron Inc., H2 2016 52
Dyskinesia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 53
Assessment by Monotherapy Products, H2 2016 54
Assessment by Combination Products, H2 2016 55
Number of Products by Stage and Target, H2 2016 57
Number of Products by Stage and Mechanism of Action, H2 2016 60
Number of Products by Stage and Route of Administration, H2 2016 63
Number of Products by Stage and Molecule Type, H2 2016 65
Dyskinesia - Dormant Projects, H2 2016 150
Dyskinesia - Dormant Projects (Contd..1), H2 2016 151
Dyskinesia - Dormant Projects (Contd..2), H2 2016 152
Dyskinesia - Discontinued Products, H2 2016 153

List of Figures

Number of Products under Development for Dyskinesia, H2 2016 13
Number of Products under Development for Dyskinesia - Comparative Analysis, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Comparative Analysis by Late Stage Development, H2 2016 19
Comparative Analysis by Clinical Stage Development, H2 2016 20
Comparative Analysis by Early Stage Products, H2 2016 21
Assessment by Monotherapy Products, H2 2016 54
Number of Products by Top 10 Targets, H2 2016 56
Number of Products by Stage and Top 10 Targets, H2 2016 56
Number of Products by Top 10 Mechanism of Actions, H2 2016 59
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59
Number of Products by Routes of Administration, H2 2016 62
Number of Products by Stage and Routes of Administration, H2 2016 62
Number of Products by Molecule Types, H2 2016 64
Number of Products by Stage and Molecule Types, H2 2016 64
  • Renewable Energy Sources Needs To Boost Global Microgrids Market
    The global market for microgrid was worth US$13.3 billion in 2015, and is anticipated to touch an estimate of US$35.2 billion by 2020. Dealers in the market for microgrids are incessantly improving the network hosting capability for renewable energy resources to excerpt an extreme amount from it, in addition to commercialization of classically costly renewable […]
  • Manufacturing Trends In The Coming Days
    The manufacturing industry may be encountering some breezes, but it is irrefutably in the middle of a technological revival that is altering the appearance, structures, and practices of the modern factory. Notwithstanding the jeopardies and in spite of recent history industrial manufacturing enterprises cannot afford to disregard these developments. Few of the trends to look […]
  • Top 10 Emerging Technologies
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or environmental jeopardies […]
  • Global Biosimilars Market To Be Led By Novartis by 2020
    Biologics, which are typically inoculated or injected, are formed in living entities, making them more challenging and costly to manufacture than the usual pills contrived from chemicals. Observing that mock-ups are mostly identical to the prototypes has also modelled specific scientific and regulatory tasks. But the US FDA and European supervisors lately have acknowledged new […]
  • Global Thyroid Gland Disorder Treatment Market To Grow Steadily
    The global thyroid gland disorder treatment market was worth US$1.8 billion in 2014 and is projected to reach a market value of US$2.4 billion in 2023 intensifying at a CAGR of 3.1% from 2015 to 2023.  The thyroid gland produces thyroid hormones that control some of the most essential functions in the human body such as stimulating […]
  • Mild Cognitive Impairment - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 124
    Mild Cognitive Impairment - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H1 2017, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate s......
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017
    Published: 11-Apr-2017        Price: US 2000 Onwards        Pages: 95
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H1 2017, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape. Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or......
  • Epilepsy - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 382
    Epilepsy - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H1 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape. Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and sho......
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 62
    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Inflammatory Demyelinating Polyneuropathy - Pipeline Review, H1 2017, provides an overview of the Chronic Inflammatory Demyelinating Polyneuropathy (Central Nervous System) pipeline landscape. Chronic inflammatory demyelinating polyneuropathy (CIDP) also called as chronic ......
  • Trigeminal Neuralgia - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 55
    Trigeminal Neuralgia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Trigeminal Neuralgia - Pipeline Review, H1 2017, provides an overview of the Trigeminal Neuralgia (Central Nervous System) pipeline landscape. Trigeminal neuralgia is a chronic pain condition that affects the trigeminal nerve, which carries sensation from face to brain. Symptoms include spontaneous attacks of pain o......
  • Nicotine Addiction - Pipeline Review, H1 2017
    Published: 15-Mar-2017        Price: US 2000 Onwards        Pages: 57
    Nicotine Addiction - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nicotine Addiction - Pipeline Review, H1 2017, provides an overview of the Nicotine Addiction (Central Nervous System) pipeline landscape. Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. Predisposing factors include age, depression, schizophrenia, post......
  • Encephalitis - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 38
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H1 2017, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and the......
  • Cluster Headache Syndrome - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 37
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2017, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender......
  • Drug Addiction - Pipeline Review, H1 2017
    Published: 08-Mar-2017        Price: US 2000 Onwards        Pages: 165
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs